Extensions to In Silico Bioactivity Predictions Using Pathway Annotations and Differential Pharmacology Analysis: Application to Xenopus laevis Phenotypic Readouts
暂无分享,去创建一个
A. Bender | Georgios Drakakis | Adam E. Hendry | S. Brewerton | G. Wheeler | M. Bodkin | David A. Evans | Sonia Liggi | Kimberley Hanson
[1] R. Glen,et al. Diversity Selection of Compounds Based on ‘Protein Affinity Fingerprints’ Improves Sampling of Bioactive Chemical Space , 2013, Chemical biology & drug design.
[2] Andreas Bender,et al. In Silico Target Predictions: Defining a Benchmarking Data Set and Comparison of Performance of the Multiclass Naïve Bayes and Parzen-Rosenblatt Window , 2013, J. Chem. Inf. Model..
[3] J. Medina-Franco,et al. Shifting from the single to the multitarget paradigm in drug discovery. , 2013, Drug discovery today.
[4] U. Eggert. The why and how of phenotypic small-molecule screens. , 2013, Nature chemical biology.
[5] P. Clemons,et al. Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.
[6] Isidro Cortes-Ciriano,et al. Experimental validation of in silico target predictions on synergistic protein targets , 2013, Journal of Cheminformatics.
[7] I. Aliagas,et al. Physicochemical and DMPK in silico models: facilitating their use by medicinal chemists. , 2013, Molecular pharmaceutics.
[8] Andreas Bender,et al. Chemogenomics Approaches to Rationalizing the Mode-of-Action of Traditional Chinese and Ayurvedic Medicines , 2013, J. Chem. Inf. Model..
[9] Dermot F McGinnity,et al. Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics. , 2013, Molecular pharmaceutics.
[10] Julio E. Peironcely,et al. How Do Metabolites Differ from Their Parent Molecules and How Are They Excreted? , 2013, J. Chem. Inf. Model..
[11] Dennis A. Smith,et al. Evolution of ADME science: where else can modeling and simulation contribute? , 2013, Molecular pharmaceutics.
[12] Maria F. Sassano,et al. Automated design of ligands to polypharmacological profiles , 2012, Nature.
[13] R. Glen,et al. Anti-cancer drug development: computational strategies to identify and target proteins involved in cancer metabolism. , 2012, Current pharmaceutical design.
[14] P. Bork,et al. Drug discovery in the age of systems biology: the rise of computational approaches for data integration. , 2012, Current opinion in biotechnology.
[15] A. Laties,et al. Cystic fibrosis transmembrane conductance regulator contributes to reacidification of alkalinized lysosomes in RPE cells. , 2012, American journal of physiology. Cell physiology.
[16] M. Gilson,et al. Public domain databases for medicinal chemistry. , 2012, Journal of medicinal chemistry.
[17] J. Medina-Franco,et al. Expanding the medicinally relevant chemical space with compound libraries. , 2012, Drug discovery today.
[18] Sean Ekins,et al. Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation. , 2012, Drug discovery today.
[19] Jeremy L Jenkins,et al. Large‐Scale QSAR in Target Prediction and Phenotypic HTS Assessment , 2012, Molecular informatics.
[20] Bo-Han Su,et al. Predictive Toxicology Modeling: Protocols for Exploring hERG Classification and Tetrahymena pyriformis End Point Predictions , 2012, J. Chem. Inf. Model..
[21] Vassilios Ioannidis,et al. ExPASy: SIB bioinformatics resource portal , 2012, Nucleic Acids Res..
[22] Igor I. Baskin,et al. Machine Learning Methods for Property Prediction in Chemoinformatics: Quo Vadis? , 2012, J. Chem. Inf. Model..
[23] Jeffrey Aubé,et al. Drug repurposing and the medicinal chemist. , 2012, ACS medicinal chemistry letters.
[24] Ryan G. Coleman,et al. ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..
[25] Guixia Liu,et al. Performance Evaluation of 2D Fingerprint and 3D Shape Similarity Methods in Virtual Screening , 2012, J. Chem. Inf. Model..
[26] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[27] Andreas Bender,et al. Recognizing Pitfalls in Virtual Screening: A Critical Review , 2012, J. Chem. Inf. Model..
[28] Pekka Tiikkainen,et al. Analysis of Commercial and Public Bioactivity Databases , 2012, J. Chem. Inf. Model..
[29] John B. O. Mitchell,et al. Predicting the mechanism of phospholipidosis , 2012, Journal of Cheminformatics.
[30] Evan Bolton,et al. PubChem's BioAssay Database , 2011, Nucleic Acids Res..
[31] Andreas Bender,et al. From in silico target prediction to multi-target drug design: current databases, methods and applications. , 2011, Journal of proteomics.
[32] Jürgen Bajorath,et al. Assessing the Confidence Level of Public Domain Compound Activity Data and the Impact of Alternative Potency Measurements on SAR Analysis , 2011, J. Chem. Inf. Model..
[33] Chris Morley,et al. Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.
[34] Sean Ekins,et al. A quality alert and call for improved curation of public chemistry databases. , 2011, Drug discovery today.
[35] Peter Murray-Rust,et al. Minimum information about a bioactive entity (MIABE) , 2011, Nature Reviews Drug Discovery.
[36] Gisbert Schneider,et al. From Hits to Leads: Challenges for the Next Phase of Machine Learning in Medicinal Chemistry , 2011, Molecular informatics.
[37] C. Jessus,et al. Unfertilized Xenopus Eggs Die by Bad-Dependent Apoptosis under the Control of Cdk1 and JNK , 2011, PloS one.
[38] M. Baccarini,et al. Raf kinases in cancer–roles and therapeutic opportunities , 2011, Oncogene.
[39] Meir Glick,et al. The role of computational methods in the identification of bioactive compounds. , 2011, Current opinion in chemical biology.
[40] George Karypis,et al. Improved machine learning models for predicting selective compounds , 2011, BCB '11.
[41] M. Vikkula,et al. KITLG mutations cause familial progressive hyper- and hypopigmentation. , 2011, The Journal of investigative dermatology.
[42] J. Arrowsmith. Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.
[43] Sean Ekins,et al. In silico repositioning of approved drugs for rare and neglected diseases. , 2011, Drug discovery today.
[44] D. Becker,et al. Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma , 2011, Cell cycle.
[45] Tudor I. Oprea,et al. Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer‐Aided Drug Repurposing , 2011, Molecular informatics.
[46] Charles Y. Lin,et al. DHODH modulates transcriptional elongation in the neural crest and melanoma , 2011, Nature.
[47] Alexander Statnikov,et al. Assessing quality and completeness of human transcriptional regulatory pathways on a genome-wide scale , 2011, Biology Direct.
[48] Jian Xu,et al. α- and β-adrenoceptors of zebrafish in melanosome movement: a comparative study between embryo and adult melanophores. , 2011, Biochemical and biophysical research communications.
[49] R. Winklbauer,et al. PDGF-A controls mesoderm cell orientation and radial intercalation during Xenopus gastrulation , 2011, Development.
[50] J. Arrowsmith. Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.
[51] L Zhang,et al. Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.
[52] S. Eaton,et al. Megalin-dependent Yellow endocytosis restricts melanization in the Drosophila cuticle , 2011, Development.
[53] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[54] M. Cisternino,et al. Noonan syndrome associated with both a new Jnk‐activating familial SOS1 and a de novo RAF1 mutations , 2010, American journal of medical genetics. Part A.
[55] Antony J. Williams,et al. ChemSpider:: An Online Chemical Information Resource , 2010 .
[56] Alexander Tropsha,et al. Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..
[57] J. Mestres,et al. In Silico Receptorome Screening of Antipsychotic Drugs , 2010, Molecular informatics.
[58] Yoshihiro Yamanishi,et al. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework , 2010, Bioinform..
[59] J. McGrath,et al. The molecular skin pathology of familial primary localized cutaneous amyloidosis , 2010, Experimental dermatology.
[60] Matt T Bianchi,et al. Targeting ligand-gated ion channels in neurology and psychiatry: is pharmacological promiscuity an obstacle or an opportunity? , 2010, BMC pharmacology.
[61] Sean Ekins,et al. Troubleshooting computational methods in drug discovery. , 2010, Journal of pharmacological and toxicological methods.
[62] B. Wall,et al. AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1) , 2010, Pigment cell & melanoma research.
[63] L. Zon,et al. Melanocytes in development and cancer , 2010, Journal of cellular physiology.
[64] Ian H. Witten,et al. The WEKA data mining software: an update , 2009, SKDD.
[65] Jürgen Bajorath,et al. From Structure–Activity to Structure–Selectivity Relationships: Quantitative Assessment, Selectivity Cliffs, and Key Compounds , 2009, ChemMedChem.
[66] Benjamin E. Deverman,et al. Cytokines and CNS Development , 2009, Neuron.
[67] Y. Nishimura,et al. Zebrafish beta-adrenergic receptor mRNA expression and control of pigmentation. , 2009, Gene.
[68] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[69] Antti Tanskanen,et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study) , 2009, The Lancet.
[70] Sorel Muresan,et al. Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds , 2009, J. Cheminformatics.
[71] John A. Tallarico,et al. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds , 2009, Nature Reviews Drug Discovery.
[72] G. Wheeler,et al. Chemical genomics identifies compounds affecting Xenopus laevis pigment cell development. , 2009, Molecular bioSystems.
[73] P. Guan,et al. A chemical genomic approach identifies matrix metalloproteinases as playing an essential and specific role in Xenopus melanophore migration. , 2009, Chemistry & biology.
[74] Bin Chen,et al. Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis , 2009, J. Chem. Inf. Model..
[75] Andreas Bender,et al. How Similar Are Similarity Searching Methods? A Principal Component Analysis of Molecular Descriptor Space , 2009, J. Chem. Inf. Model..
[76] Andreas Bender,et al. Ligand-Target Prediction Using Winnow and Naive Bayesian Algorithms and the Implications of Overall Performance Statistics , 2008, J. Chem. Inf. Model..
[77] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[78] R. Solé,et al. Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.
[79] J. Lehár,et al. High-order combination effects and biological robustness , 2008, Molecular systems biology.
[80] Tudor I. Oprea,et al. WOMBAT and WOMBAT‐PK: Bioactivity Databases for Lead and Drug Discovery , 2008 .
[81] J. Qu,et al. [Expression of dopamine receptor D2 and adenosine receptor A2A in human retinal pigment epithelium]. , 2007, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology.
[82] Yoichi Matsubara,et al. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype–phenotype relationships and overlap with Costello syndrome , 2007, Journal of Medical Genetics.
[83] T. Ban. Fifty years chlorpromazine: a historical perspective , 2007, Neuropsychiatric disease and treatment.
[84] Michael J Ackerman,et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy , 2007, Nature Genetics.
[85] Bin Zhou,et al. Large-Scale Annotation of Small-Molecule Libraries Using Public Databases , 2007, J. Chem. Inf. Model..
[86] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[87] O. Rath,et al. MAP kinase signalling pathways in cancer , 2007, Oncogene.
[88] ヨッヘン クロック,et al. The use of opioid receptor antagonists , 2007 .
[89] R. Scolyer,et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma , 2007, Modern Pathology.
[90] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[91] Tudor I. Oprea,et al. Target, chemical and bioactivity databases – integration is key , 2006 .
[92] R. Snyder,et al. Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database. , 2006, Pharmacogenomics.
[93] Z. Deng,et al. Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.
[94] Monya Baker,et al. Open-access chemistry databases evolving slowly but not surely , 2006, Nature Reviews Drug Discovery.
[95] M. Pittelkow,et al. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical significance. , 2006, The Journal of investigative dermatology.
[96] Jürgen Drews,et al. Case histories, magic bullets and the state of drug discovery , 2006, Nature Reviews Drug Discovery.
[97] Richard Morphy,et al. The physicochemical challenges of designing multiple ligands. , 2006, Journal of medicinal chemistry.
[98] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[99] William Lingran Chen,et al. Chemoinformatics: Past, Present, and Future† , 2006, J. Chem. Inf. Model..
[100] S. Aspengren,et al. Studies of pigment transfer between Xenopus laevis melanophores and fibroblasts in vitro and in vivo. , 2006, Pigment cell research.
[101] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[102] Alexander E. Kel,et al. TRANSPATH®: an information resource for storing and visualizing signaling pathways and their pathological aberrations , 2005, Nucleic Acids Res..
[103] Alexander E. Kel,et al. TRANSFAC® and its module TRANSCompel®: transcriptional gene regulation in eukaryotes , 2005, Nucleic Acids Res..
[104] Wolfram Kress,et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 , 2005, Nature Genetics.
[105] Katsuaki Sato,et al. Carbonic Anhydrase II Is a Tumor Vessel Endothelium–Associated Antigen Targeted by Dendritic Cell Therapy , 2005, Clinical Cancer Research.
[106] R. Morphy,et al. Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.
[107] M. Klagsbrun,et al. A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. , 2005, Cytokine & growth factor reviews.
[108] F. López-Muñoz,et al. History of the discovery and clinical introduction of chlorpromazine. , 2005, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[109] L. Larue,et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression , 2005, Nature.
[110] J. Moreau,et al. RLIP mediates downstream signalling from RalB to the actin cytoskeleton during Xenopus early development , 2004, Mechanisms of Development.
[111] T. Golub,et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. , 2004, Cancer cell.
[112] Suzie Chen,et al. Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development , 2004, Journal of Molecular Medicine.
[113] Andreas Bender,et al. Similarity Searching of Chemical Databases Using Atom Environment Descriptors (MOLPRINT 2D): Evaluation of Performance , 2004, J. Chem. Inf. Model..
[114] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[115] Richard Morphy,et al. From magic bullets to designed multiple ligands. , 2004, Drug discovery today.
[116] J. D. Dal Porto,et al. B cell antigen receptor signaling 101. , 2004, Molecular immunology.
[117] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[118] Sergei Egorov,et al. Pathway studio - the analysis and navigation of molecular networks , 2003, Bioinform..
[119] J. Radich,et al. The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.
[120] I. Dozmorov,et al. Decreased glycogen synthase kinase 3‐beta levels and related physiological changes in Bacillus anthracis lethal toxin‐treated macrophages , 2003, Cellular microbiology.
[121] Dragos Horvath,et al. Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.
[122] J. Lehár,et al. Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[123] Barry J. Dickson. Molecular Mechanisms of Axon Guidance , 2002, Science.
[124] N. Gough. Science's Signal Transduction Knowledge Environment , 2002 .
[125] A. Paller,et al. Incontinentia pigmenti: a review and update on the molecular basis of pathophysiology. , 2002, Journal of the American Academy of Dermatology.
[126] J. Fryns,et al. PTPN11 mutations in LEOPARD syndrome , 2002, Journal of medical genetics.
[127] M. Schartl,et al. Activation of p59Fyn Leads to Melanocyte Dedifferentiation by Influencing MKP-1-regulated Mitogen-activated Protein Kinase Signaling* , 2002, The Journal of Biological Chemistry.
[128] K. Varani,et al. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line , 2001, British journal of pharmacology.
[129] G. Ryffel,et al. Dimerization co-factor of hepatocyte nuclear factor 1/pterin-4alpha-carbinolamine dehydratase is necessary for pigmentation in Xenopus and overexpressed in primary human melanoma lesions. , 2001, The American journal of pathology.
[130] C. Betsholtz,et al. Developmental roles of platelet‐derived growth factors , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.
[131] R. Fujii. The regulation of motile activity in fish chromatophores. , 2000, Pigment cell research.
[132] B. Roth,et al. The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? , 2000 .
[133] R. Buscà,et al. Cyclic AMP a key messenger in the regulation of skin pigmentation. , 2000, Pigment cell research.
[134] J. Drews. Drug discovery: a historical perspective. , 2000, Science.
[135] I. Dominguez,et al. Dorsal downregulation of GSK3beta by a non-Wnt-like mechanism is an early molecular consequence of cortical rotation in early Xenopus embryos. , 2000, Development.
[136] B. Dickson,et al. Analysis of Drosophila photoreceptor axon guidance in eye-specific mosaics. , 2000, Development.
[137] I. Toda,et al. Identification of androgen receptor protein and 5α-reductase mRNA in human ocular tissues , 2000, The British journal of ophthalmology.
[138] Stephen L. Johnson,et al. Zebrafish sparse corresponds to an orthologue of c-kit and is required for the morphogenesis of a subpopulation of melanocytes, but is not essential for hematopoiesis or primordial germ cell development. , 1999, Development.
[139] M. Nash,et al. Serotonin-2A Receptor mRNA Expression in Rat Retinal Pigment Epithelial Cells , 1998, Ophthalmic Research.
[140] Michael S. Deiner,et al. Netrin-1 and DCC Mediate Axon Guidance Locally at the Optic Disc: Loss of Function Leads to Optic Nerve Hypoplasia , 1997, Neuron.
[141] Philippe Soriano. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. , 1997, Development.
[142] J. Wood,et al. Protein kinase C activation by serotonin potentiates agonist-induced stimulation of cAMP production in cultured rat retinal pigment epithelial cells. , 1997, Experimental eye research.
[143] B. Neel,et al. Specific modulation of ectodermal cell fates in Xenopus embryos by glycogen synthase kinase. , 1995, Development.
[144] J. Smith,et al. Carbonic anhydrase type II in regenerating retinal pigment epithelium. A histochemical study in the rabbit , 1993, Experientia.
[145] D. Sugden,et al. Protein kinase C activation antagonizes melatonin-induced pigment aggregation in Xenopus laevis melanophores , 1992, The Journal of cell biology.
[146] R. Spritz,et al. Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[147] R. Andersson,et al. Characterization of pigment aggregating α2‐adrenoceptors of fish melanophores by use of different agonists after partial irreversible receptor inactivation , 1989, British journal of pharmacology.
[148] Philippe Vayer,et al. Toward in silico structure-based ADMET prediction in drug discovery. , 2012, Drug discovery today.
[149] Adam E. Hendry,et al. Chemical genetics and drug discovery in Xenopus. , 2012, Methods in molecular biology.
[150] P. Ertl,et al. Computational analysis of structure-activity relationships. , 2010, Progress in medicinal chemistry.
[151] Yanli Wang,et al. PubChem: Integrated Platform of Small Molecules and Biological Activities , 2008 .
[152] M. Panicker,et al. Serotonin 2A (5-HT2A) Receptor Function: Ligand-Dependent Mechanisms and Pathways , 2007 .
[153] Thorsten Meinl,et al. KNIME: The Konstanz Information Miner , 2007, GfKl.
[154] J. Mestres,et al. Connecting small molecules to nuclear receptor pathways. , 2007, Current topics in medicinal chemistry.
[155] Sean Ekins,et al. Pathway mapping tools for analysis of high content data. , 2007, Methods in molecular biology.
[156] Meir Glick,et al. Enrichment of High-Throughput Screening Data with Increasing Levels of Noise Using Support Vector Machines, Recursive Partitioning, and Laplacian-Modified Naive Bayesian Classifiers , 2006, J. Chem. Inf. Model..
[157] Susumu Goto,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..
[158] N. Rahimi,et al. Hepatocyte growth factor receptor in human RPE cells: implications in proliferative vitreoretinopathy. , 1999, Investigative ophthalmology & visual science.
[159] Alberto Maria Segre,et al. Programs for Machine Learning , 1994 .
[160] H. Shichi,et al. Regional distribution of lipoxygenase activities in porcine ciliary epithelium. , 1991, Journal of ocular pharmacology.